Shots:

• The US FDA has accepted the PR of BLA for TicoVac to prevent TBE in patients aged ≥1year with an anticipated PDUFA date in Aug 2021. If approved- the vaccine may help reduce the risk of TBE for people traveling to endemic areas
• The BLA is based on clinical trials that assess TicoVac across two age groups (aged 1-15yrs. and 16-65yrs.). The studies showed pooled seropositivity rates 99-100% and 94-99% following three doses respectively
• The real-world studies demonstrated that the vaccine is 96-99% effective in people who have received at least 2 doses of the vaccine and 2-3 doses of the vaccine were shown to be sufficient to provide a long-lasting immune memory

 ­ Ref: Pfizer | Image: Pfizer